Screening for depression in primary care with Patient Health Questionnaire-9 (PHQ-9): A systematic review
-Patient Health Questionnaire 9 (PHQ-9) has been widely validated for depression screening in primary care in high- and low-income countries.-A two-stage screening is recommended for depression.-A Mental Health Professional (MHP) should confirm the diagnosis by use of a semi-structured diagnostic in...
Gespeichert in:
Veröffentlicht in: | Journal of affective disorders 2021-01, Vol.279, p.473-483 |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | -Patient Health Questionnaire 9 (PHQ-9) has been widely validated for depression screening in primary care in high- and low-income countries.-A two-stage screening is recommended for depression.-A Mental Health Professional (MHP) should confirm the diagnosis by use of a semi-structured diagnostic interview.
Depression is a leading cause of disability. International guidelines recommend screening for depression and the Patient Health Questionnaire 9 (PHQ-9) has been identified as the most reliable screening tool. We reviewed the evidence for using it within the primary care setting.
We retrieved studies from MEDLINE, Embase, PsycINFO, CINAHL and the Cochrane Library that carried out primary care-based depression screening using PHQ-9 in populations older than 12, from 1995 to 2018.
Forty-two studies were included in the systematic review. Most of the studies were cross-sectional (N=40, 95%), conducted in high-income countries (N=27, 71%) and recruited adult populations (N=38, 90%). The accuracy of the PHQ-9 was evaluated in 31 (74%) studies with a two-stage screening system, with structured interview most often carried out by primary care and mental health professionals. Most of the studies employed a cut-off score of 10 (N=24, 57%, total range 5 – 15). The overall sensitivity of PHQ-9 ranged from 0.37 to 0.98, specificity from 0.42 to 0.99, positive predictive value from 0.09 to 0.92, and negative predictive value from 0.8 to 1.
Lack of longitudinal studies, small sample size, and the heterogeneity of primary-care settings limited the generalizability of our results.
PHQ-9 has been widely validated and is recommended in a two-stage screening process. Longitudinal studies are necessary to provide evidence of long-term screening effectiveness. |
---|---|
ISSN: | 0165-0327 1573-2517 |
DOI: | 10.1016/j.jad.2020.09.131 |